BeOne Medicines

Company in Cambridge, Massachusetts, USA.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Nº Q30260298 ★★

Peu commune · Organisations

BeOne Medicines

Company in Cambridge, Massachusetts, USA.

Texte en anglais

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Dernier prix

—

Prix plancher

—

Médiane 7 j

—

Ventes 30 j

Fourchette 30 j

—

En circulation

Cours

Voir le tableau

Date	médiane	Min	Max	ventes

Historique des ventes

Dernière vente: —
Moyenne 30 j: —
Plus bas 30 j: —
Plus haut 30 j: —
Ventes 7 j: 0
Ventes 30 j: 0

Aucune vente pour l'instant.

Ventes anonymes : ni acheteur ni vendeur. Les chiffres ne comptent que les ventes entre joueurs.

Sur Wikipédia

Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab (brand name of Tevimbra), a checkpoint inhibitor, and zanubrutinib (brand name of Brukinsa), a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.

Texte : Wikipédia en anglais, CC BY-SA 4.0. ·